These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 22398062)

  • 1. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
    J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
    Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease.
    D'Incà R; Annese V; di Leo V; Latiano A; Quaino V; Abazia C; Vettorato MG; Sturniolo GC
    Aliment Pharmacol Ther; 2006 May; 23(10):1455-61. PubMed ID: 16669960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent.
    Suenaert P; Bulteel V; Vermeire S; Noman M; Van Assche G; Rutgeerts P
    Inflamm Bowel Dis; 2005 Jul; 11(7):667-73. PubMed ID: 15973122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease.
    Hilsden RJ; Meddings JB; Sutherland LR
    Gastroenterology; 1996 May; 110(5):1395-403. PubMed ID: 8613043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
    Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
    Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease.
    Suenaert P; Bulteel V; Lemmens L; Noman M; Geypens B; Van Assche G; Geboes K; Ceuppens JL; Rutgeerts P
    Am J Gastroenterol; 2002 Aug; 97(8):2000-4. PubMed ID: 12190167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal permeability in patients with Crohn's disease and their healthy relatives.
    Katz KD; Hollander D; Vadheim CM; McElree C; Delahunty T; Dadufalza VD; Krugliak P; Rotter JI
    Gastroenterology; 1989 Oct; 97(4):927-31. PubMed ID: 2506103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.
    Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z
    Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut permeability to lactulose and mannitol differs in treated Crohn's disease and celiac disease patients and healthy subjects.
    Vilela EG; Torres HO; Ferrari ML; Lima AS; Cunha AS
    Braz J Med Biol Res; 2008 Dec; 41(12):1105-9. PubMed ID: 19148373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased gastric and intestinal permeability in patients with Crohn's disease.
    Wyatt J; Oberhuber G; Pongratz S; Püspök A; Moser G; Novacek G; Lochs H; Vogelsang H
    Am J Gastroenterol; 1997 Oct; 92(10):1891-6. PubMed ID: 9382060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha.
    Söderholm JD; Streutker C; Yang PC; Paterson C; Singh PK; McKay DM; Sherman PM; Croitoru K; Perdue MH
    Gut; 2004 Dec; 53(12):1817-24. PubMed ID: 15542521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.